Immunophenotypic and genomic characterization of papillary carcinomas of the breast

Journal of Pathology

Volumn 226, Issue 3, 2012, Pages 427-441

  Duprez, Raphaëlle ^a   Wilkerson, Paul M ^a   Lacroix Triki, Magali ^a,b   Lambros, Maryou B ^a   MacKay, Alan ^a   Hern, Roger A ^a   Gauthier, Arnaud ^a,c   Pawar, Vidya ^a   Colombo, Pierre Emanuel ^a   Daley, Frances ^a   Natrajan, Rachael ^a   Ward, Eric ^a   MacGrogan, Gaëtan ^d   Arbion, Flavie ^e   Michenet, Patrick ^f   Weigelt, Britta ^g   Vincent Salomon, Anne ^c   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT BERGONIÉ   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f Centre Hospitalier Regional   (France)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

breast cancer; comparative genomic hybridization; immunohistochemistry; in situ hybridization; mutation; papillary carcinoma; tissue microarrays

Indexed keywords

ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; BREAST PAPILLARY CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENCAPSULATED PAPILLARY CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INVASIVE DUCTAL CARCINOMA OF NO SPECIAL TYPE; INVASIVE PAPILLARY CARCINOMA; LYMPH NODE METASTASIS; MICRODISSECTION; MUTATIONAL ANALYSIS; ONCOGENE; PAPILLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SOLID PAPILLARY CARCINOMA;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHATIC METASTASIS; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ESTROGEN;

EID: 84856048158     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3032     Document Type: Article

References (80)

1. Tavassoli FA, Devilee P,. Tumours of the Breast. International Agency for Research of Cancer (IARC): Lyon, 2003.
2. Sotiriou C, Pusztai L,. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
3. Weigelt B, Baehner FL, Reis-Filho JS,. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010; 220: 263-280.
4. Weigelt B, Horlings HM, Kreike B, et al., Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
5. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730.
6. Lopez-Garcia MA, Geyer FC, Natrajan R, et al., Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol 2010; 222: 64-75.
7. Weigelt B, Geyer FC, Natrajan R, et al., The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220: 45-57.
8. Vincent-Salomon A, Gruel N, Lucchesi C, et al., Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
9. Gruel N, Lucchesi C, Raynal V, et al., Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010; 46: 2399-2407.
10. Weigelt B, Geyer FC, Horlings HM, et al., Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009; 22: 1401-1414.
11. Bertucci F, Orsetti B, Negre V, et al., Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27: 5359-5372.
12. Lacroix-Triki M, Suarez PH, Mackay A, et al., Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-298.
13. Marchio C, Iravani M, Natrajan R, et al., Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301-315.
14. Marchio C, Iravani M, Natrajan R, et al., Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215: 398-410.
15. Weigelt B, Geyer FC, Reis-Filho JS,. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192-208.
16. Reis-Filho JS, Lakhani SR,. Breast cancer special types: why bother? J Pathol 2008; 216: 394-398.
17. Persson M, Andren Y, Mark J, et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106: 18740-18744.
18. Tognon C, Knezevich SR, Huntsman D, et al., Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376. (Pubitemid 41039103)
19. Solorzano CC, Middleton LP, Hunt KK, et al., Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg 2002; 184: 364-368. (Pubitemid 35287362)
20. Grabowski J, Salzstein SL, Sadler GR, et al., Intracystic papillary carcinoma: a review of 917 cases. Cancer 2008; 113: 916-920.
21. Pal SK, Lau SK, Kruper L, et al., Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat 2010; 122: 637-645.
22. Rakha EA, Gandhi N, Climent F, et al., Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol 2011; 35: 1093-1103.
23. Hill CB, Yeh IT,. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 2005; 123: 36-44. (Pubitemid 40068840)
24. Collins LC, Schnitt SJ,. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 2008; 52: 20-29. (Pubitemid 350265188)
25. Collins LC, Carlo VP, Hwang H, et al., Intracystic papillary carcinomas of the breast: a re-evaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 2006; 30: 1002-1007. (Pubitemid 44264950)
26. Nassar H, Qureshi H, Volkanadsay N, et al., Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 2006; 30: 501-507. (Pubitemid 43740152)
27. Tsuda H, Uei Y, Fukutomi T, et al., Different incidence of loss of heterozygosity on chromosome 16q between intraductal papilloma and intracystic papillary carcinoma of the breast. Jpn J Cancer Res 1994; 85: 992-996. (Pubitemid 24325018)
28. Oikawa M, Nagayasu T, Yano H, et al., Intracystic papillary carcinoma of breast harbors significant genomic alteration compared with intracystic papilloma: genome-wide copy number and LOH analysis using high-density single-nucleotide polymorphism microarrays. Breast J 2011; 17: 427-430.
29. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al., Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2011; [Epub ahead of print: DOI: 10.1002/path.2974].
30. Chin K, DeVries S, Fridlyand J, et al., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541. (Pubitemid 44854748)
31. Adelaide J, Finetti P, Bekhouche I, et al., Integrated profiling of basal and luminal breast cancers. Cancer Res 2007; 67: 11565-11575.
32. Andre F, Job B, Dessen P, et al., Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
33. Natrajan R, Lambros MB, Geyer FC, et al., Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009; 48: 351-365.
34. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al., Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
35. Tavassoli FA, Devilee P,. Tumours of the Breast. International Agency for Research of Cancer (IARC): Lyon, 2003.
36. Elston CW EI,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
37. Loo LW, Grove DI, Williams EM, et al., Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004; 64: 8541-8549. (Pubitemid 39552066)
38. Melchor L, Honrado E, Huang J, et al., Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007; 13: 7305-7313.
39. Harvey JM, Clark GM, Osborne CK, et al., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481. (Pubitemid 29220854)
40. Reis-Filho JS, Savage K, Lambros MB, et al., Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridization analysis. Mod Pathol 2006; 19: 999-1009.
41. Wolff AC, Hammond ME, Schwartz JN, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
42. Tan DS, Marchio C, Jones RL, et al., Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44. (Pubitemid 352009225)
43. Ali HR, Dawson SJ, Blows FM, et al., A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER positive breast cancer. J Pathol 2011; [Epub ahead of print: DOI: 10.1002/path.2976].
44. Callagy GM, Pharoah PD, Pinder SE, et al., Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-2475.
45. Dawson SJ, Makretsov N, Blows FM, et al., BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103: 668-675.
46. Abdel-Fatah TM, Powe DG, Ball G, et al., Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 2010; 222: 388-399.
47. Savage K, Lambros MB, Robertson D, et al., Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90-101. (Pubitemid 46121857)
48. Savage K, Leung S, Todd SK, et al., Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008; 110: 245-256. (Pubitemid 351793874)
49. Parry S, Savage K, Marchio C, et al., Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 2008; 61: 1045-1050.
50. Nielsen TO, Hsu FD, Jensen K, et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374. (Pubitemid 39100473)
51. Marchio C, Natrajan R, Shiu KK, et al., The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008; 216: 399-407.
52. Coe BP, Ylstra B, Carvalho B, et al., Resolving the resolution of array CGH. Genomics 2007; 89: 647-653. (Pubitemid 46589944)
53. Tan DS, Lambros MB, Natrajan R, et al., Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737-754. (Pubitemid 47077258)
54. Gunnarsson R, Staaf J, Jansson M, et al., Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697-711. (Pubitemid 351847582)
55. Mackay A, Tamber N, Fenwick K, et al., A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 481-498.
56. Natrajan R, Weigelt B, Mackay A, et al., An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
57. Reis-Filho JS, Drury S, Lambros MB, et al., ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008; 40: 809-810; author reply, 810-812. (Pubitemid 351913662)
58. Geyer FC, Weigelt B, Natrajan R, et al., Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562-573.
59. Lambros MB, Natrajan R, Reis-Filho JS,. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007; 38: 1105-1122. (Pubitemid 47058171)
60. Lambros MB, Simpson PT, Jones C, et al., Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006; 86: 398-408.
61. Fumagalli D, Gavin PG, Taniyama Y, et al., A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010; 10: 101.
62. Lambros MB, Wilkerson PM, Natrajan R, et al., High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform. Lab Invest 2011; 91: 1491-1501.
63. Elsheikh S, Green AR, Aleskandarany MA, et al., CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325-335. (Pubitemid 351644857)
64. Roylance R, Gorman P, Papior T, et al., A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 2006; 25: 6544-6553. (Pubitemid 44607087)
65. Di Cosimo S, Baselga J,. Phosphoinositide 3-kinase mutations in breast cancer: a 'good' activating mutation? Clin Cancer Res 2009; 15: 5017-5019.
66. Abdel-Fatah TM, Powe DG, Agboola J, et al., The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010; 220: 419-434.
67. Gravier E, Pierron G, Vincent-Salomon A, et al., A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 2010; 49: 1125-1134.
68. Jonsson G, Staaf J, Vallon-Christersson J, et al., Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010; 12: R42.
69. Russnes HG, Vollan HK, Lingjaerde OC, et al., Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010; 2: 38ra47.
70. Vincent-Salomon A, Lucchesi C, Gruel N, et al., Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-1965. (Pubitemid 351551104)
71. Robanus-Maandag EC, Bosch CA, Kristel PM, et al., Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003; 201: 75-82. (Pubitemid 37121205)
72. Powell DJ, Jr., Russell J, Nibu K, et al., The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998; 58: 5523-5528. (Pubitemid 28551140)
73. Ledent C, Marcotte A, Dumont JE, et al., Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene 1995; 10: 1789-1797.
74. Coppee F, Gerard AC, Denef JF, et al., Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene 1996; 13: 1471-1482. (Pubitemid 26354195)
75. Burniat A, Jin L, Detours V, et al., Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology 2008; 149: 5107-5117.
76. Bumaschny V, Urtreger A, Diament M, et al., Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model. Breast Cancer Res 2004; 6: R116-129.
77. Zhang ZT, Pak J, Huang HY, et al., Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-1980. (Pubitemid 32458029)
78. Rosner A, Miyoshi K, Landesman-Bollag E, et al., Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002; 161: 1087-1097. (Pubitemid 34988396)
79. McCarthy A, Lord CJ, Savage K, et al., Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J Pathol 2009; 219: 306-316.
80. Ashworth A, Lord CJ, Reis-Filho JS,. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.